These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Pulmonary infiltrates in Hodgkin's disease. II. Therapeutic possibilities and efficacy of treatment]. Zelechowska JA; Zomer J; Golebiowska D; Buraczewski J Nowotwory; 1974; 24(2):101-6. PubMed ID: 4849542 [No Abstract] [Full Text] [Related]
5. [Thoracic tumors after treatment for Hodgkin disease]. Watine O; Morel P; Bauters F; Ribet M Ann Chir; 1995; 49(3):225-31. PubMed ID: 7793843 [TBL] [Abstract][Full Text] [Related]
6. [Focal bone lesions in Hodgkin's disease]. Karnicka-Mlodkowska H; Jordan E Pol Tyg Lek; 1974 Dec; 29(49):2135-7. PubMed ID: 4438175 [No Abstract] [Full Text] [Related]
7. [Lung involvement in Hodgkin's disease. Study of 49 cases. III. Treatment. Evolution and prognosis]. Puras Tellaeche A; Frieyro Segui JE Rev Clin Esp; 1982 Mar; 164(5):293-8. PubMed ID: 7100542 [No Abstract] [Full Text] [Related]
11. [Use of salicylates in the treatment of Hodgkin's disease]. Czownicki Z Pol Tyg Lek; 1973 May; 28(16):571-4. PubMed ID: 4705814 [No Abstract] [Full Text] [Related]
12. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397 [TBL] [Abstract][Full Text] [Related]
13. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study. Salloum E; Doria R; Farber LR; Roberts KB; Cooper DL Cancer J Sci Am; 1995; 1(4):267-73. PubMed ID: 9166487 [TBL] [Abstract][Full Text] [Related]
14. Pulmonary Hodgkin's disease with cavitary lesions. Gopinathan H; Sataline LR Ohio State Med J; 1966 Mar; 62(3):238-41. PubMed ID: 5908334 [No Abstract] [Full Text] [Related]
15. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease. Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984 [TBL] [Abstract][Full Text] [Related]
16. [Cellular immunity in Hodgkin's disease in complete remission]. Burchardt K Pol Tyg Lek; 1980 Dec; 35(50):1937-40. PubMed ID: 7291045 [No Abstract] [Full Text] [Related]
17. Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease. Viviani S; Bonfante V; Santoro A; Zanini M; Devizzi L; Di Russo AD; Soncini F; Villani F; Ragni G; Valagussa P; Bonadonna G Cancer J Sci Am; 1999; 5(5):275-82. PubMed ID: 10526668 [TBL] [Abstract][Full Text] [Related]
18. Preparation for marrow transplantation in Hodgkin's and non-Hodgkin's lymphoma using Bu/CY. Avalos BR; Klein JL; Kapoor N; Tutschka PJ; Klein JP; Copelan EA Bone Marrow Transplant; 1993 Aug; 12(2):133-8. PubMed ID: 8401359 [TBL] [Abstract][Full Text] [Related]
19. The cure of Hodgkin's Disease. Healy JB; Moriarty M J Ir Med Assoc; 1972 Oct; 65(19):486-9. PubMed ID: 5073341 [No Abstract] [Full Text] [Related]
20. Electromyographic studies in patients with pulmonary carcinoma and Hodgkin's disease. Wochnik-Dyjas D; Niewiadomska M; Leszczyńska H Pol Med J; 1970; 9(1):173-80. PubMed ID: 5437034 [No Abstract] [Full Text] [Related] [Next] [New Search]